| Document |
Document Title |
|
WO/2024/052790A1 |
The colour of flotation froth (3) is determined by Illuminating the froth (3), capturing a digital image of the froth (3) in a multispectral light sensor (6), and using specular reflection intensity of an illumination source (1) from gas...
|
|
WO/2024/050639A1 |
Described herein are devices and methods for fluid manipulation using electrowetting. More specifically, this disclosure provides devices and methods for manipulating fluids using a digital microfluidics ("DMF") device. For example, a fl...
|
|
WO/2024/052243A1 |
The present invention describes the use of curcumin in endogenous marking together with one or more polyethylene glycols.
|
|
WO/2024/052434A1 |
The present invention relates to a SoxB1 factor variant comprising (a) the HMG (high-mobility group) domain of any one of the amino acid sequences of SEQ ID NOs: 1 to 3, wherein the amino acid alanine at position 61 of the HMG-domain is ...
|
|
WO/2021/136715A9 |
The present invention relates to a method and a device for quantitatively detecting the presence or absence of an analyte in a liquid sample, comprising an analyte detection assembly comprising a source of electromagnetic radiation, a me...
|
|
WO/2024/054987A1 |
Compositions and methods for diagnosis and treatment of increased risk for mild traumatic brain injury are disclosed.
|
|
WO/2024/052453A1 |
The invention relates to a receiving device (200) comprising a receiving region (205) for receiving a cartridge (105) for an analysis device for analysing a fluid arranged in the cartridge (105). The cartridge (105) can be inserted via a...
|
|
WO/2024/052917A1 |
Methods of treating cancer comprising reducing expression or function of eukaryotic initiation factor 4E-binding protein 1 (EIF4EBP1) or EIF4EBP2 in a cell of the cancer, wherein the function is binding Eukaryotic translation initiation ...
|
|
WO/2024/052329A1 |
The invention concerns a method for determining the existence of or susceptibility to panic based upon the presence of serum sortilin related VPS10 domain containing receptor 3 (SORCS3); a kit for performing the afore method(s); at least...
|
|
WO/2024/053519A1 |
Disclosed are a kit for diagnosing Alzheimer's disease and a pharmaceutical composition for treating Alzheimer's disease that use EDIL3 or a nucleic acid that encodes EDIL3 as an indicator or a target.
|
|
WO/2024/050856A1 |
A method and system for assisting a blood cell analyzer in determining abnormal platelet aggregation. The method comprises the following steps: S1, placing a blood sample into a blood cell analyzer for platelet counting; S2, when the blo...
|
|
WO/2024/054904A1 |
The present disclosure provides, in some aspects, humanized immunodeficient mouse models that support long-term engraftment and function of human T cells, natural killer cells, and myeloid cells, without the need for conditioning.
|
|
WO/2024/054892A1 |
Disclosed herein are engineered peptides for treatment of diseases or conditions such as cancer. Also disclosed herein are pharmaceutical compositions containing engineered peptides of the present disclosure. Also disclosed herein are me...
|
|
WO/2024/054666A1 |
One variation of a method includes, during execution of a tracer test: triggering release of a tracer load into air in an aerosol zone by a dispenser transiently arranged in the aerosol zone, the tracer load including a concentration of ...
|
|
WO/2024/052566A1 |
The present invention relates generally to the field of antibody detection, and in particular relates to methods involving the detection of autoantibodies relating to Sjögren's syndrome in a sample comprising patient bodily fluid. In pa...
|
|
WO/2024/051675A1 |
Use of CD38 +HLA-DR +CD8 + T cells as a graft-versus-host disease biomarker and use of CD38 +HLA-DR +CD8 + T cells in the preparation of a graft-versus-host disease detection reagent. Compared with healthy volunteers and patients without...
|
|
WO/2024/051463A1 |
The present application relates to an antibody specifically binding to ROR1, a conjugated drug thereof, and a preparation method therefor and use thereof. The inventor of the present application develops an antibody against ROR1. The ant...
|
|
WO/2024/054946A1 |
Described herein are methods for identifying a biological state such as pancreatic cancer in a subject. For example, a method may include obtaining protein data, transcriptomic data, genomic data, lipidomic data, or metabolomic data of a...
|
|
WO/2024/054898A1 |
Disclosed herein include methods, compositions, and kits suitable for use in treating cancer in a subject. In some embodiments, the method comprises administration of onvansertib and a PART inhibitor (e.g., olaparib, niraparib, and AZD53...
|
|
WO/2024/050860A1 |
The present invention relates to the technical field of medical biology, and particularly, to use of RUNX2 as a marker in preparing a diagnosis or detection reagent for a malignant phyllodes tumor. The detection reagent can assist in, ac...
|
|
WO/2024/054644A2 |
Featured are compositions, methods, and apparatuses for biosynthetic organs, or organoids, that replicate tissues of the human female reproductive system (e.g., ovarian or uterine tissues). In particular, the disclosure features methods ...
|
|
WO/2024/051646A1 |
The present invention relates to a method and a kit for diagnosing MIDD. Specifically, provided is a method for diagnosing MIDD, which comprises the following steps: (1) detecting lactic acid in urine; and (2) comparing same with the con...
|
|
WO/2024/054640A1 |
Embodiments presented provide for a method for detecting emissions. The method establishes a map that is used with prevailing wind conditions to establish a point source location for methane gas emissions.
|
|
WO/2024/052842A1 |
The present invention relates to a non-invasive device (100) and method (400) for detecting RNA associated disease based on the activity of the biological sample. The device (100) and method (400) encompass passing of the biological samp...
|
|
WO/2024/054632A2 |
In various embodiments alpha helical peptide-based bridges for molecular biosensing "on-chip" are disclosed. The Peptide-based bridges serve as common bridges for great diversity of biosensing applications and targets including nucleic a...
|
|
WO/2024/051106A1 |
A preparation and use of an anti-IL4i1 nano antibody. The anti-IL4i1 nano antibody has three unique complementarity-determining regions CDR1, CDR2, and CDR3, and nine sequences of the anti-IL4i1 nano antibody are selected in total. Furth...
|
|
WO/2024/050596A1 |
The present disclosure generally relates to methods of determining the probability of live birth and to methods of, and compositions for, increasing the probability of live birth. The methods disclosed include an analysis of the level an...
|
|
WO/2024/054678A2 |
Certain embodiments provide an isolated antibody or fragment thereof having affinity for fentanyl or analog thereof, as well as methods of use thereof. Certain embodiments provide a method for treating fentanyl or analog related overdose...
|
|
WO/2024/052864A1 |
The invention relates to substantially complete vaginal microbiota preparations for treating infertility and therapeutic methods to do so.
|
|
WO/2024/054382A1 |
The invention generally relates to methods for employing mass spectrometry techniques to sequence and analyze biological molecules, such as glycan. In certain aspects, the invention provides methods for sequencing a biological molecule t...
|
|
WO/2024/054190A1 |
The present invention relates to a method (100) for synthesizing molecularly imprinted polymeric nanoparticles which are used for detecting target molecule, bacteria, virus, protein, lipid, aptamer, carbohydrate, extracellular vesicle (e...
|
|
WO/2024/054436A1 |
Provided are methods of treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), e.g., TMA after HSCT, in human patients having elevated levels of thrombomodulin (TM) and syndecan-1 (SYND1) compared t...
|
|
WO/2024/053887A1 |
This invention relates to a Copine1 gene marker for prognosing the metastasis of HER2-positive breast cancer and a use thereof. Specifically, the present invention relates to a biomarker composition for prognosing the metastasis of HER2-...
|
|
WO/2024/052158A1 |
A method of detecting, predicting or monitoring the progress of amyloid angiopathy, ARIA (amyloid -related imaging abnormalities) or CAA (cerebral amyloid angiopathy) in an individual. The method comprises the step of: determining the pr...
|
|
WO/2023/287815A9 |
Disclosed are methods for assessing the severity of a coronavirus infection through the measurement of caspase 4 and methods of treating a coronavirus infection comprising administering to an infected subject an inhibitor of CASP4 or its...
|
|
WO/2024/053693A1 |
Provided are: an automatic measurement pendulum-type oiliness friction tester that can automatically measure the angular velocity or oscillation angle of a damping vibration in a vertical plane of a pendulum without relying on a visual r...
|
|
WO/2024/053874A1 |
The present invention relates to a method and device for non-destructive prediction of functional components in plants. In the present invention, a predictive model that represents the correlation between the spectral images of a plant a...
|
|
WO/2024/049290A1 |
The invention provides a method for characterization of a structure of a protein using a first probe and a second probe, wherein the method comprises: an exposure stage comprising: (i) exposing the protein to the second probe, (ii) provi...
|
|
WO/2024/044831A1 |
A fuel sensor (1) for detecting the percentage of ethanol in a fuel mixture of gasoline and ethanol is described. The fuel sensor comprises a casing (2) defining a seat (9) for a PCB (8), wherein the casing (2) comprises, externally, fla...
|
|
WO/2024/049046A1 |
The present disclosure relates to a peptide binding to Trop 2 and a use thereof, wherein, in an attempt to find a peptide having an ability of specifically binding to Trop 2, a peptide (amino acid sequence: CSTLNVESC) that selectively bi...
|
|
WO/2024/050023A1 |
The present disclosure relates to the treatment of a cancer in a human subject where the treatment includes continuing administration of a T cell receptor (TCR) therapy in subjects whose ctDNA levels do not exceed baseline following admi...
|
|
WO/2024/047178A1 |
Disclosed is a method and compounds useful for performing said method for simultaneous synthesis of a plurality of oligonucleotide molecules, and more specifically for orthogonal synthesis of at least two different oligonucleotide molecu...
|
|
WO/2024/046476A1 |
The present invention relates to the treatment of herpes simplex virus (HSV) infection using an anti-HSV antibody. In particular, the anti-HSV antibody specifically binds to the glycoprotein D (gD) of herpes simplex virus-1 (HSV-1) and h...
|
|
WO/2024/048644A1 |
This carrier for delivering a target substance to MUC6 expression-negative cancer tissues contains a molecule having the activity of binding to mannose. The cancer tissues may be MUC6 expression-negative gastric cancer tissues arising fr...
|
|
WO/2024/049522A1 |
Apparatus and methods for extracellular vesicle enrichment are described in which apparatus may be used to create plasma preparations that are enriched in EV-containing fluid sample. Generally, one variation of a method may generally com...
|
|
WO/2024/044854A1 |
This invention provides chronic graft-versus-host disease (cGVHD) biomarker panels for use in diagnostic and risk assignment methods. More particularly, the invention relates to particular combinations of biomarkers for diagnosing cGVHD ...
|
|
WO/2024/045429A1 |
A performance test method for a full-automatic sample preparation system, the method comprising a precision test and a bias test, and the measurement of a total-moisture loss rate. The precision test and the bias test involve the followi...
|
|
WO/2024/046605A1 |
The compounds of formula (IA) or formula (IB) or a salt thereof. The compounds can be used as reference products in the determination of the administration of ligandrol to a subject.
|
|
WO/2024/048418A1 |
Provided is a diagnostic antibody that is capable of detecting PD-L1 in tumors for novel therapies for feline tumors targeting PD-1/PD-L1. The anti-PD-L1 antibody contains: (a) an L-chain having CDR1 that has the amino acid sequence ES...
|
|
WO/2024/050553A1 |
Provided herein are compositions and methods for determining telomere length. In some embodiments, methods include attaching a telomere tagging probe to a 3' end of the telomere to generate a tagged telomere sequence and use of a splint ...
|
